Imagen Network (IMAGE) Enhances Peer Discovery with Grok-Driven Personalization Engines 
Nicolas Law Group Announces the Publication of a Report on Increasing DUI Arrests in Illinois in 2024 
JAR Audio Rebrands to JAR Podcast Solutions to Reflect Marketers’ Focus on ROI-Driven Branded Podcasts 
Steam22 Launches $STM Token, Surpasses $2M Market Cap on Day One as Blockchain-Powered Sportsbook Gains Momentum 
The 10 Best Online Courses For IT Professionals – Practical, Certified, And Worth Your Time XOMA Announces Heather L. Franklin Joins its Board of Directors
EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ: XOMA) announced today Heather…
ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) —…
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
ALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program…
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical…
Voyager Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene…
Codex DNA Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21 ORIC-533…
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
– Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- –…
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission…
Akoya Reports 53% Revenue Growth in the Second Quarter of 2021
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension…
Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
– Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected…
Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif., Aug. 10, 2021…
Zosano Pharma Reports Second Quarter 2021 Financial Results
FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance
DURHAM, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug….
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Commenced dosing in Phase 3 PATHFNDR-1 study – – Phase 1 single-ascending dose data…
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
CB4211 was well-tolerated and appeared safe with no serious adverse events Robust reductions in ALT…
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218…